Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Amplia Therapeutics has given investors a fresh reason to look beyond pancreatic cancer, signing an agreement with the Australia New Zealand Gynaecological Oncology Group to run a new ovarian cancer study of its lead drug narmafotinib.

The planned PRROSE trial will test narmafotinib alongside standard chemotherapy, carboplatin and paclitaxel, in about 15-20 patients with high-grade serous ovarian cancer who have responded poorly to initial platinum-based chemotherapy ahead of planned interval debulking surgery. That is a small study, but for an ASX biotech with a market value around $72 million, it is potentially useful clinical optionality without requiring a swing-for-the-fences phase three cheque just yet.

Why ovarian cancer, and why now?

The logic is biological as much as commercial. Amplia says ovarian cancer is a major target for FAK inhibition because these tumours often show higher FAK expression and a fibrous tumour environment. FAK, or focal adhesion kinase, is involved in the way cancer cells interact with their surroundings, and narmafotinib is designed to inhibit this pathway.

The unmet need is also clear. Amplia says about one in five ovarian cancer patients do not respond adequately to initial chemotherapy, which can limit their ability to proceed to surgery and worsen outcomes. PRROSE will look first at safety, but it will also explore whether adding narmafotinib can increase the proportion of patients who become eligible for successful surgical resection. That gives the trial a practical clinical question: can the drug help turn a poor pre-surgery responder into a better surgical candidate?

The credibility kicker: ANZGOG

For investors, the ANZGOG tie-up matters. This is not Amplia simply adding another line to a slide deck. ANZGOG is the peak gynaecological cancer research organisation across Australia and New Zealand, with a broad clinical trials network spanning major hospitals. The study is investigator initiated, led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated by ANZGOG.

Chief executive Dr Chris Burns framed the study as a deliberate broadening of the FAK inhibitor program. “Patients with ovarian cancer who do not respond to initial chemotherapy have very limited treatment options and this study will provide an opportunity to assess whether narmafotinib can improve outcomes for these patients,” he said.

Dr Ho added that the trial reflects ANZGOG’s ability to bring together clinical investigators in areas of high unmet need, with the study designed to generate meaningful evidence for future treatment options.

Pancreatic data remains the main valuation anchor

The ovarian study is useful, but the market will still be taking most of its cues from pancreatic cancer. Amplia’s ACCENT trial has been testing narmafotinib with gemcitabine and Abraxane in first-line advanced pancreatic cancer. The company’s latest ovarian cancer release cites a 31% response rate and interim progression-free survival of 7.6 months for ACCENT, while subsequent market reports on the March mature ACCENT data referred to a centrally reviewed objective response rate of 35.9% and median overall survival of 11.1 months.

That broader context is important because narmafotinib’s investment case is no longer just “interesting science”. It now has human efficacy signals, albeit from studies that still need the harder proof demanded by larger, controlled trials.

The wrinkle: AMPLICITY reminded everyone biotech is not knitting

Investors should also keep the April AMPLICITY halt in mind. Amplia stopped recruitment in that pancreatic cancer trial after three dose-limiting toxicities linked to the FOLFIRINOX chemotherapy regimen, while stating no toxicity concerns had been identified with narmafotinib. The episode does not torpedo the drug, but it does underline the everyday reality of oncology drug development: combinations can be as tricky as the compound itself.

That makes PRROSE interesting because it pairs narmafotinib with a different standard chemotherapy backbone in a different fibrotic cancer setting. Success would not just add an ovarian cancer opportunity; it would also support the broader contention that FAK inhibition can travel across tumour types.

The investor read-through

PRROSE is early, small and exploratory. It will not deliver registration-grade evidence, and investors should not dress it up as such. But it does three useful things for Amplia.

It broadens narmafotinib beyond pancreatic cancer, brings a respected oncology trials group into the tent, and collects tissue and blood biomarker data that could sharpen future patient selection. In biotech land, where the distance between “promising” and “proven” can be measured in years and millions of dollars, that is a sensible next move.

The share price will still dance to pancreatic data, trial design, funding runway and regulatory progress. But with ovarian cancer now formally in the clinic queue, Amplia has added another string to the narmafotinib bow - and this one has a clear biological rationale rather than a mere whiff of opportunism.

X2M Connect has sketched out a much larger Australian growth plan, signing a non-binding memorandum of understanding with Mawson Business Advisory to develop what it calls an Integrated Smart Community Offering, or ISCO. The pitch is bold: give retirement villages, land lease communities, caravan parks, residential subdivisions and master planned estates one technology and operations stack rather than a patchwork of up to 20 vendors.

For investors, the attraction is not merely the gadgetry. X2M wants to be the prime contractor on each estate agreement, taking all revenue and retaining the right to add margin on subcontracted services. Contracts are intended to run for 10 years, which would push the company further towards the kind of long-duration recurring revenue model small-cap tech investors tend to prize.

The retirement village angle

The target market is not trivial. X2M cites more than 2,500 retirement villages in Australia, housing around 200,000 residents, with the retirement village sector carrying a capital value of $6.2 billion in 2026. The land lease community sector adds more than 900 communities and about 70,000 Australians.

The ISCO bundle would include automated meter reading for electricity, water and gas, AI-driven utility management, resident billing, land lease administration, VoIP and mobile virtual network operator services, community solar and batteries, maintenance and help desk support. In plainer terms, X2M is trying to move from selling smart infrastructure into becoming an embedded operating platform for private communities.

That is potentially more lucrative, but also more complex. Selling meter infrastructure is one thing. Running a single-bill, connectivity, utility and estate management ecosystem is another. Investors should note the MoU is non-binding, so the next proof point is conversion into executable estate contracts.

Private 5G is the sizzle, but data is the steak

The eye-catching claim is that private 5G infrastructure could replace NBN connections inside estates. X2M says the network could support real-time machine-to-machine communication for applications such as smart street lighting, automated valve control, driverless shuttles, energy balancing and predictive fault detection.

Still, the deeper commercial logic sits in X2M’s data platform. The company’s Flexible Micro Engine is designed to connect with different meters, sensors, devices, networks and protocols. That device-agnostic capability matters because estates are unlikely to have neat, uniform infrastructure. X2M says its platform turns raw utility and device signals into structured, AI-ready data, which is the foundation for operating these communities more efficiently.

The Mawson relationship is also important. Mawson brings property, landowner and facilities management relationships, and is described as one of X2M’s largest shareholders. Mawson Advisory managing director Julian Kirzner said the single-title multiple-dwelling market represents a “significant opportunity for integrated facilities management services” and described X2M’s platform as “world leading” based on its international deployments.

The revenue prize and the assumptions

X2M says the partnership can add momentum to its Australian pipeline, which already stands at about 5,800 lots across binding and non-binding agreements, with an estimated value of $11.8 million if all households adopt the company’s offering. That last phrase is doing some heavy lifting. Full household adoption is an upside case, not banked revenue.

The company also says the total addressable market of its existing utility customers exceeds $600 million in upfront revenue and $40 million in annual recurring revenue, again assuming all households across those municipalities adopt X2M’s technology.

X2M’s installed base gives the story some ballast. The company says it has connected more than 500,000 devices and serves 89 enterprise and government customers across South Korea, Japan, Taiwan, the Middle East and Australia. It also says about half of its existing customers place repeat orders, suggesting the business can deepen relationships once it wins a seat at the table.

Management’s view

Chief executive and managing director Mohan Jesudason said the company had spent more than a decade building a platform that can “connect and process data at scale and power real AI applications across utility and community infrastructure”.

He said the Mawson partnership meant X2M could go to market with a complete solution, including “a single agreement, a single bill, 5G connectivity, AI-driven utility management, full facilities operations and a 10-year managed service”.

That is a neat summary of the investment thesis: X2M wants to own the digital plumbing of smart communities, not merely supply a few taps and meters.

The investor read-through

This is a strategically interesting move for X2M because it broadens the company’s addressable market and could improve revenue visibility if the 10-year managed-service model is executed. It also gives X2M a clearer domestic growth narrative alongside its offshore utility deployments.

But the risks are equally clear. The MoU is non-binding, the revenue numbers depend heavily on adoption assumptions, and the ISCO model requires X2M to coordinate multiple service layers across connectivity, billing, utilities and facilities operations. That could lift revenue per estate, but it also raises execution demands.

For now, investors have been given a bigger story rather than a finished financial outcome. The next markers to watch are binding estate contracts, pricing detail, margin structure, capex requirements for private 5G deployment and evidence that operators are willing to hand one small-cap technology company such a central role in running their communities.

Motio Ltd (ASX: MXO) has used its April trading update to put a cleaner story in front of investors: less software distraction, more digital place-based media. The company has completed the divestment of Spawtz, re-focused on media, paid down $750,000 of debt owed to OML and reaffirmed its FY25 revenue guidance of $8.4 million to $8.8 million, excluding Spawtz. It also restated its FY25 cash EBITDA target at more than $1.2 million, including office rent expenses.

That is the sort of update small-cap investors tend to like because it contains actual operating signposts rather than the usual “strategic review” blancmange. The key issue is whether Motio can keep scaling revenue without letting costs gallop alongside it like a caffeinated greyhound.

Q3 trading keeps the growth thesis alive

The headline trading metric is that Q3 revenue was up 31 per cent compared with the same time last year and tracking to budget. Motio also said Q4 forward revenue was strong, giving management enough confidence to reaffirm guidance rather than hide behind the sofa until year-end.

The revenue mix is also worth watching. Year-to-date revenue was shown as 65 per cent agency, 8 per cent direct, 15 per cent local and 12 per cent programmatic. The Q3 comparison was similar: 64 per cent agency, 8 per cent direct, 17 per cent local and 11 per cent programmatic. That consistency matters because a lumpy microcap media business can look wonderful one month and like the back end of a bus the next. Motio’s point is that the variables are staying relatively low through the year.

A bigger network, but measurement is the magic word

Motio says its network now includes 1,500 high-definition digital displays across 1,000 high-value locations. The pitch is not simply that these are screens on walls. The company is selling a mix of out-of-home reach, digital precision, video storytelling and contextual content in places where people naturally dwell: cafes, medical centres, indoor sports facilities and venues. Market Index similarly describes Motio as a digital place-based network operating across cafes, medical centres, indoor sports venues and bar/pub settings.

The most important forward-looking operational item may be audience measurement. Motio said industry measurement was confirmed for a June launch. For advertisers, measurement is the difference between a nice screen network and a buyable media channel. Better measurement can make it easier for agencies to justify spend, compare formats and allocate campaigns. For Motio, it could help convert its “remembered, not just seen” branding into a more accountable sales proposition.

Debt down, cash improving

The balance sheet message is straightforward: cash is “solid and increasing”, and debt to OML is now $1.05 million after the $750,000 repayment. That is not the same as having a fortress balance sheet, but for a company of Motio’s scale it is meaningful. Less debt means less leakage, more optionality and fewer awkward conversations with lenders when the ad cycle wobbles.

Motio also says it is continuing conservative capital investment while assessing accretive opportunities. That is a delicate line. Small listed media companies often talk about scale, but acquisitions only help if they add earnings without importing a basket of costs, integration headaches and heroic synergy assumptions.

Valuation has moved with the story

Motio’s own presentation says the company was being valued at about one times revenue on the ASX - with a market capitalisation of approximately $15.19 million. Against the reaffirmed FY25 revenue guidance range of $8.4 million to $8.8 million, that implies a simple market capitalisation-to-guided revenue comparison of about 1.7 to 1.8 times.

That does not make the stock cheap or dear by itself. It simply means the market is putting some value on the cleaner media focus, improving profitability and revenue growth profile. Market Index notes Motio has not paid dividends, which is unsurprising for a small company still prioritising scale and operating leverage.

The investor read-through

For investors, the update is less about one flashy number and more about the combination: Spawtz gone, guidance reaffirmed, Q3 revenue up 31 per cent, Q4 forward revenue described as strong, debt reduced and audience measurement nearing launch. The bear case is still the usual microcap cocktail of execution risk, thin liquidity, media-cycle sensitivity and dependence on continued agency demand. The bull case is that Motio has become a simpler, more scalable media business just as its network and measurement tools are maturing.

The next update, flagged for the second week of June, will need to show that Q4 momentum is more than a hopeful green pie chart. For now, Motio has at least given investors something tangible to measure - and in small-cap media, that is already a useful start.

Swift TV has landed the sort of approval that micro-cap technology companies like to shout about, and with some justification. The Perth-based enterprise entertainment and engagement group says it has completed the final approval stage needed to integrate Netflix officially into the Swift TV platform, after a multi-year certification process involving Google and Netflix. For a company capped at about $10.1 million, this is not a trivial badge for the pool room.

Why Netflix matters

The practical win is that Swift TV customers can offer end users direct access to Netflix through the television interface, while still preserving the features that enterprise customers care about: secure access controls, auto logout, alerts and emergency messaging, even over active Netflix viewing. In the managed accommodation world - mining camps, aged care, hospitals, oil and gas facilities and hotels - the humble in-room TV is becoming more than a screen bolted to a wall. It is entertainment, messaging, engagement and, when needed, a safety channel.

Swift says the approval followed technical, security and user experience testing for certified enterprise entertainment devices. It also says Swift TV is currently the only enterprise connected TV product in Australia operating within Google’s enterprise operator framework, enabling direct Google Play Store access through the Swift TV interface. That is the sort of infrastructure detail that can sound dry, until a procurement department starts comparing one platform with another.

Chief executive Brian Mangano called completion of the Netflix process “a significant milestone” and said it validated the platform’s ability to meet the standards of one of the world’s leading streaming brands. His more pointed observation was that “as Netflix limits support for casting”, approved devices such as Swift TV become increasingly important. Translation: if guests, patients or workers cannot reliably cast Netflix from their phones, the television platform itself needs to do the heavy lifting.

The commercial angle

For investors, the key issue is not whether people like Netflix. Spoiler alert: they do. The question is whether Netflix approval helps Swift convert deployments, win tenders, lift margins and deepen recurring revenue.

There is some recent context here. Swift reported that its new-generation Swift TV platform had gone live at seven customer sites or facilities, representing 2,758 screens in the first seven weeks, with another eight sites scheduled for completion by 1 June 2026. It also ordered 5,000 additional devices from a Google-certified supplier to meet anticipated demand, while reporting new wins in oil and gas, aged care and hospitals.

That matters because Swift has been trying to shift away from lower-margin reselling and project-style work toward its own subscription-led platform. In its H1 FY26 presentation, the company reported total revenue of $7.5 million, down from $9.1 million, with subscription revenue at $6.5 million and project revenue at $1 million. However, enterprise EBITDA was $1.1 million, equal to a 15 per cent margin, and management said the product mix shift was intended to prioritise recurring revenue over shorter-term communications project work.

The balance sheet question

The Netflix tick does not magically solve the balance sheet. At 31 March 2026, Swift reported $2 million in cash and deposits, helped by receipt of $1.45 million in R&D tax incentive funds during the quarter. Earlier H1 numbers showed total liabilities of $15.1 million and negative net assets of $5.7 million, although the company said net assets had improved by $1.6 million since 30 June 2025.

So, investors should view this as a strategic de-risking event, not a revenue announcement with dollars attached. It sharpens Swift’s competitive pitch, particularly where end-user experience and enterprise control need to co-exist. But the next proof points remain familiar: device rollouts, customer conversions, recurring revenue growth, margin expansion and cash discipline.

The verdict

Swift TV has earned a useful seat at the streaming table. Netflix approval gives the platform credibility, reduces a potential procurement objection and fits neatly with the company’s push into scalable enterprise accommodation markets. For a small ASX technology stock, the news is meaningful because it strengthens the product, not because it instantly changes the profit and loss statement.

The screen is now approved. Investors will be watching whether management can turn that approval into installed units, sticky subscriptions and, ultimately, a cleaner financial picture.

Adisyn Ltd (ASX: AI1) has added a serious defence industry name to its newly formed Advisory Board, appointing former Israeli Air Defense Colonel Tamir Zimber as it seeks to turn its graphene-based radar absorption work into a commercial defence opportunity.

Zimber’s CV is not exactly short of acronyms or hardware. He was responsible for operational execution of Israel’s Iron Dome, Arrow, David’s Sling and Patriot systems, giving him direct experience with some of the world’s most closely watched air and missile defence platforms. He is currently Senior Director for Air Defense Systems in India at Israel Aerospace Industries, where Adisyn says he oversees multi-billion-dollar defence programs and manages engagement with government and military stakeholders.

For investors, the appointment matters because Adisyn is trying to move its radar signature reduction technology beyond the lab coat stage. The company has said graphene-enhanced composite materials have achieved up to 20dB radar signature reduction in laboratory testing, which it says could materially reduce the detectability of UAV and defence platforms. That is still early-stage work, but the strategic prize is obvious: drones are becoming cheaper, more numerous and more important, while the systems designed to detect them are becoming more sophisticated.

From clever material to usable product

Adisyn’s core technology pitch remains its graphene materials platform, including a patented low-temperature atomic layer deposition process targeting semiconductor applications. The defence angle is a second front, but it is fast becoming the more colourful one.

Last month, Adisyn secured exclusive worldwide commercialisation rights for graphene-based radar absorption technology under a binding Licence and Research Agreement with Ramot, the commercialisation arm of Tel Aviv University. That agreement included a 12-month research program focused on improving radar absorption performance, manufacturability and scalability, with the company previously flagging an expected program cost of less than $100,000.

The economic structure is also worth noting. 2D Radar Absorbers Ltd, the vehicle established for the radar absorption opportunity, is 81 per cent held by 2D Generation Ltd, a wholly owned Adisyn subsidiary, with Ramot holding 19 per cent. Ramot is also entitled to a 4 per cent royalty on net sales under the licence structure.

Zimber’s consideration is not cash, but options representing 1 per cent of 2D Radar Absorbers’ issued capital as at incorporation, exercisable at NIS 0.01 per share, subject to board approval. The options vest over 24 months, with a six-month cliff and monthly vesting thereafter. That aligns him with the success of the subsidiary rather than simply adding another consulting line item to the P&L.

The gap between proof and procurement

Managing director Arye Kohavi said Zimber’s appointment was “a significant step in the development of our defense strategy”, adding that his experience operating and deploying advanced air defence systems would give Adisyn insight into “both the operational requirements and commercial pathways in this sector”.

That last phrase is doing a lot of work. Defence markets are not won by good science alone. Procurement cycles can be long, validation requirements are exacting, and the end users are not generally impressed by investor-deck enthusiasm. Materials need to work in the real world, not merely under controlled laboratory conditions.

Adisyn knows this, judging by the way it has framed the Advisory Board. Its stated role is to help prioritise radar-related activities, translate technical capability into operationally relevant solutions, engage with commercial and government stakeholders, and open global defence networks.

That is the right shopping list. The market will now want evidence that it can be executed.

Market has already re-rated the story

The investor backdrop is lively. ASX data showed AI1 last at 21 cents, with a market capitalisation of about $223.6 million, following a sharp run in the stock during 2026. Market Index data shows AI1 closed at 21 cents on 1 May, up materially from 4.4 cents at the end of June 2025.

That sort of rerating means expectations are no longer modest. The company is being priced less like a managed IT services business and more like an emerging advanced materials play with semiconductor and defence optionality.

The appointment of Zimber strengthens the defence narrative, but it does not by itself validate the technology commercially. The next investor markers are likely to be further testing, real-world UAV integration, industrial manufacturing partnerships and signs of genuine customer engagement. Adisyn has put a decorated operator in the tent. Now it needs to show that the tent can become a factory, a supply chain and eventually a revenue stream.